JMV5884 CDK5 inhibitor (RGNCY-0130)
Per 10 mg
JMV5884 is the most potent of a series of compounds to uniquely inhibit CDK5 by targeting a site other than the ATP pocket. JMV5884 was shown to inhibit the proliferation of U87 glioblastoma cells in vitro. By targeting CDK5 at a novel site outside the ATP binding site, JMV5884 presents an attractive lead for the treatment of glioblastoma as it potentially bypasses the limitations of existing ATP-competitive inhibitors targeting CDK5/p25 interface. Therefore, JMV5884 is a promising lead for glioblastoma treatment and provides a new therapeutic perspective for neurodegenerative disease.
Systematic Name: 2-(((6-amino-1H-benzo[d]imidazol-2-yl)thio)methyl)-3-(3-chlorophenyl)quinazolin-4(3H)-one
Mol Wt: 433.91
Peyressatre M et al. Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation. Front Chem. 2020 Aug 19;8:691.
There are no uploaded files